2011年10月4日,美国食品和药品管理局(FDA)发布公告,要求在贝伐珠单抗(bevacizumab)的说明书中增加卵巢衰竭、下颌骨坏死和静脉血栓栓塞的风险提示[1]。贝伐珠单抗为重组的人源化IgG1单克隆抗体,可与血管内皮生长因子(VEGF)结合,阻碍VEGF与其受体在内皮细胞表 On October 4, 2011, the U.S. Food and Drug Administration (FDA) issued a bulletin announcing the need to increase the risk of ovarian failure, mandibular necrosis, and venous thromboembolism in bevacizumab’s instructions [1]. Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and blocks the expression of VEGF and its receptor in the endothelial cell surface